COMMUNIQUÉS West-GlobeNewswire

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
27/06/2025
TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual [...]
Orphalan Partners with MAP International and the Wilson Disease Association to Provide Life-Changing Medicine to Underserved Communities
27/06/2025
FOR IMMEDIATE RELEASE Orphalan Partners with MAP International and the Wilson Disease Association to Provide Life-Changing Medicine to Underserved Communities Paris, France —27, June, 2025 — Orphalan SA, a global [...]
Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US
27/06/2025
June 27, 2025 Announcement no. 18 Initiation of commercialization of ProNephro AKI TM (NGAL) for diagnostic use in the US COPENHAGEN, DENMARK and BOSTON, MA, USA, June 27, 2025 – BioPorto A/S (“BioPorto” or the “Company [...]
Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering
27/06/2025
SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
27/06/2025
WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences
27/06/2025
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences Halle (Saale) / Munich, Germany, June 27, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage [...]
Tilray Medical publie une recherche pionnière sur la pharmacocinétique des formulations de THC et de CBD
27/06/2025
La nouvelle étude fournit des informations sur la biodisponibilité des formulations de cannabis thérapeutique à des fins thérapeutiques NEW YORK, 27 juin 2025 (GLOBE NEWSWIRE) -- Tilray Medical, une division de Tilray [...]
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26/06/2025
VANCOUVER, British Columbia and BOSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering [...]
CorMedix Inc. Announces Proposed Public Offering of Common Stock
26/06/2025
BERKELEY HEIGHTS, N.J., June 26, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and [...]
Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
26/06/2025
WAYNE, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]
Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation
26/06/2025
Smoking, the leading cause of preventable death and disease, continues to affect nearly 29 million adults in the U.S. alone If approved, cytisinicline will be the first new FDA-approved pharmacotherapy option for [...]
Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades
26/06/2025
Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more [...]
Achieve Life Sciences Announces Proposed Underwritten Public Offering
26/06/2025
SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel
26/06/2025
Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of 2026 Tech transfer [...]
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
26/06/2025
TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025, [...]
Basel Medical Obtains Waiver of Lock-Up for Potential Strategic Fund Raising
26/06/2025
Singapore, June 26, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) , today announced that Cathay Securities, Inc., as the representative of the several underwriters of the Company’s [...]
Lifeward Announces Closing of $2.6 Million Public Offering
26/06/2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of [...]
Résultats de l’Assemblée Générale Mixte de Cellectis du 26 juin 2025
26/06/2025
NEW YORK, 26 juin 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d’édition de génome TALEN® pour [...]
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
26/06/2025
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene [...]

Pages